Cassiopeia myeloma
WebHigh-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma … Web13 Jun 2024 · The results were taken from the randomized, open-label phase 3 CASSIOPEIA trial (NCT02541383) in patients with transplant-eligible multiple myeloma …
Cassiopeia myeloma
Did you know?
Web22 Oct 2024 · Topline findings from the second part of the phase 3 CASSIOPEIA clinical trial showed that the primary end point of progression-free survival (PFS) was met with … Web4 Feb 2024 · 1 Introduction Multiple myeloma (MM) is the second most common hematological malignancy, with over 170 000 new diagnosis per year worldwide ( 1 ). MM usually is a symptom-producing cancer causing predominantly bone pain, pathological fractures, fatigue and infections ( 2 ).
Web19 Jul 2024 · Based on data from part 1 of the phase III CASSIOPEIA trial, in September 2024, the FDA granted approval to daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) for adults with newly diagnosed multiple myeloma who are eligible for ASCT. 6,7 An interim analysis from part 2 of the trial … Web17 Mar 2024 · 142. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet …
WebLeo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, discusses an update on the Cassiopeia trial (NCT02541383), a study which is in... Web20 Aug 2024 · Recommended frontline treatment of transplant-eligible newly diagnosed multiple myeloma (MM; NDMM) includes induction therapy, high-dose melphalan and …
Web9 Aug 2024 · Prof. Phillippe Moreau (University Hospital of Nantes, France) discussed the findings from the randomised, open-label, multicentre, phase 3 CASSIOPEIA trial and …
Web2 Feb 2024 · People with untreated multiple myeloma would welcome a new option for first-line treatment . 3.1 . Patient experts explained that multiple myeloma is a relapsing and remitting disease and can include severe symptoms. The first remission is often the 'best' remission because people are at their fittest. With each indian railway login irctcWebCASSIOPEIA Multiple Myeloma Hub Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma You need to enable … indian railway luggage charges per kgWeb6 May 2024 · Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The ... location opal hirsonWebThe NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specif … indian railway luggage rateWeb28 May 2024 · Methods: CASSIOPEIA is a 2-part, randomized, open-label, phase 3 study in TE NDMM. Pts received 4 cycles ind and 2 cycles cons with D-VTd or VTd. 886 pts who … indian railway luggage booking chargesWeb8 Apr 2024 · CASSIOPEIA was a randomized, open-label, phase III trial evaluating the inclusion of daratumumab with VTd before and after ASCT for transplant-eligible patients … indian railway luggage chargesWebTreatment for multiple myeloma can often help control symptoms and improve quality of life. But myeloma usually can't be cured, which means additional treatment is needed when … indian railway luggage tracking